Biological properties of human skeletal myoblasts genetically modified to simultaneously overexpress the pro-angiogenic factors vascular endothelial growth Factor-A and fibroblast growth Factor-4

Journal of Physiology and Pharmacology

Volumn 65, Issue 2, 2014, Pages 193-207

  Zimna, A ^a   Janeczek, A ^a   Rozwadowska, N ^a   Fraczek, M ^a   Kucharzewska, P ^b   Rucinski, M ^c   Mietkiewski, T ^c   Kurpisz, M ^a  

^a INSTITUTE OF HUMAN GENETICS   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c Voivodship Hospital   (Poland)

Author keywords

Fibroblast growth factor; Myocardial infarction; Skeletal myoblasts; Therapeutic angiogenesis; Vascular endothelial growth factor

Indexed keywords

CONNEXIN 43; FIBROBLAST GROWTH FACTOR 4; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; FGF4 PROTEIN, HUMAN; VEGFA PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA MODIFICATION; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC TRANSFECTION; HEART INFARCTION; HUMAN; HUMAN CELL; HYPOXIA; MYOBLAST; OXIDATIVE STRESS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; ANGIOGENESIS; METABOLISM; MYOCARDIAL INFARCTION;

CELL CYCLE; CELL PROLIFERATION; ELECTROPORATION; FIBROBLAST GROWTH FACTOR 4; GENE EXPRESSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MYOBLASTS, SKELETAL; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899649625     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Menasche P. Skeletal myoblasts and cardiac repair. J Mol Cell Cardiol 2008; 45: 545-553.
2. Jain M, DerSimonian H, Brenner DA, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001; 103: 1920-1927.
3. Menasche P, Hagege AA, Vilquin JT, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003; 41: 1078-1083.
4. Ghostine S, Carrion C, Souza LC, et al. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation 2002; 106 (Suppl. 1): I131-I136.
5. Horackova M, Arora R, Chen J, et al. Cell transplantation for treatment of acute myocardial infarction: unique capacity for repair by skeletal muscle satellite cells. Am J Physiol Heart Circ Physiol 2004; 287: H1599-H1608.
6. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002; 136: 54-71.
7. Hao X, Mansson-Broberg A, Grinnemo KH, et al. Myocardial angiogenesis after plasmid or adenoviral VEGFA165 gene transfer in rat myocardial infarction model. Cardiovasc Res 2007; 73: 481-487.
8. Kanga SW, Lim HW, Seo SW, Jeon O, Lee M, Kim BS. Nanosphere-mediated delivery of vascular endothelial growth factor gene for therapeutic angiogenesis in mouse ischemic limbs. Biomaterials 2008; 29: 1109-1117.
9. Scott RC, Rosano JM, Ivanov Z, et al. Targeting VEGFencapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J 2009; 23: 3361-3367.
10. Garbern JC, Minami E, Stayton PS, Murry CE. Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials 2011; 32: 2407-2416.
11. Cho KR, Choi JS, Hahn W, et al. Therapeutic angiogenesis using naked DNAexpressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg 2008; 34: 857-863.
12. Shyu KG, Chang H, Isner JM. Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hyper-cholesterolemic rabbit model with acute hind limb ischemia. Life Sci 2003; 73: 563-579.
13. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003; 9: 604-613.
14. Yang Y, Gruwel ML, Dreessen de Gervai P, et al. MRI study of cryoinjury infarction in pig hearts: i. Effects of intrapericardial delivery of bFGF/VEGF embedded in alginate beads. NMR Biomed 2012; 25: 177-188.
15. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-581.
16. Rissanen TT, Markkanen JE, Arve K, et al. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J 2003; 17: 100-102.
17. Rozwadowska N, Fiszer D, Siminiak T, Kalawski R, Kurpisz M. Evaluation of in vitro culture of human myoblasts for tissue autotransplants to the post-infarcted heart. Pol Heart J 2002; 57: 233-237.
18. Bialas M, Krupka M, Janeczek A, et al. Transient and stable transfections of mouse myoblasts with genes coding for proangiogenic factors. J Physiol Pharmacol 2011; 62: 219-228.
19. Ciecierska A, Chodkowska K, Motyl T, Sadkowski T. Myogenic cells applications in regeneration of post-infarction cardiac tissue. J Physiol Pharmacol 2013; 64: 401-408.
20. Kosaka N, Sakamoto H, Terada M, Ochiya T. Pleiotropic function of FGF-4: its role in development and stem cells. Dev Dyn 2009; 238: 265-276.
21. Suzuki K, Murtuza B, Smolenski RT, et al. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factorexpressing skeletal myoblasts. Circulation 2001; 104 (Suppl. 1): I207-I212.
22. Ye L, Zhang W, Su LP, et al. Nanoparticle based delivery of hypoxia-regulated VEGF transgene system combined with myoblast engraftment for myocardial repair. Biomaterials 2011; 32: 2424-2431.
23. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000; 102: 898-901.
24. Ozawa CR, Banfi A, Glazer NL, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004; 113: 516-527.
25. Ye L, Haider HKh, Jiang S, et al. Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1. Eur J Heart Fail 2007; 9: 15-22.
26. Ahluwalia A, Narula J, Jones MK, Deng X, Tarnawski AS. Impaired angiogenesis in aging myocardial microvascular endothelial cells is associated with reduced importin alpha and decreased nuclear transport of Hif 1alpha: mechanistic implication. J Physiol Pharmacol 2010; 61: 133-139.
27. Besse S, Boucher F, Linguet G, et al. Intramyocardial protein therapy with vascular endothelial growth factor (VEGF-165) induces functional angiogenesis in rat senescence myocardium. J Physiol Pharmacol 2010; 61: 651-661.
28. PaxDb http://pax-db.org/#!home
29. Gene Cards http://www.genecards.org/
30. Combs DM, Yutzey EK. Heart valve development regulatory networks in development and disease. Circ Res 2009; 105: 408-421.
31. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004; 56: 549-580.
32. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1. Mol Cell Biol 1996; 16: 4604-4613.
33. Rissanen TT, Markkanen JE, Gruchala M, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003; 92: 1098-1106.
34. Trovato-Salinaro A, Belluardo N, Frinchi M, et al. Regulation of connexin gene expression during skeletal muscle regeneration in the adult rat. Am J Physiol Cell Physiol 2009; 296: C593-C606.
35. Yablonka-Reuveni Z, Seger R, Rivera AJ. Fibroblast growth factor promotes recruitment of skeletal muscle satellite cells in young and old rats. J Histochem Cytochem 1999; 47: 23-42.
36. Xia JH, Xie AN, Zhang KL, Xu L, Zheng XY. The vascular endothelial growth factor expression and vascular regeneration in infracted myocardium by skeletal muscle satellite cells. Chin Med J 2006; 119: 117-121.
37. Germani A, Di Carlo A, Mangoni A, et al. Vascular endothelial growth factor modulates skeletal myoblast function. Am J Pathol 2003; 163: 1417-1428.
38. Becker C, Lacchini S, Muotri AR, et al. Skeletal muscle cells expressing VEGF induce capillary formation and reduce cardiac injury in rats. Int J of Cardiol 2006; 113: 348-354.
39. Megeney LA, Rudnicki MA. Determination versus differentiation and the MyoD family of transcription factors. Biochem Cell Biol 1995; 73: 723-732.
40. Breitbart RE, Liang CS, Smoot LB, Laheru DA, Mahdavi V, Nadal-Ginard B. A fourth human MEF2 transcription factor, hMEF2D, is an early marker of the myogenic lineage. Development 1993; 118: 1095-1106.
41. Bouchentouf M, Benabdallah BF, Bigey P, Yau TM, Scherman D, Tremblay JP. Vascular endothelial growth factor reduced hypoxia-induced death of human myoblasts and improved their engraftment in mouse muscles. Gene Ther 2008; 15: 404-414.
42. Retuerto MA, Beckmann JT, Carbray J, et al. Angiogenic pretreatment to enhance myocardial function after cellular cardiomyoplasty with skeletal myoblasts. J Thorac Cardiovasc Surg 2007; 133: 478-484. e2.